FindTrial
Sign In

Observational study to evaluate safety and efficacy of fix dose combination of Metformin, glimePiride, and voglibose in Type 2 diabetes mellitus patients

A Prospective, obseRvational, multicenter study to evaluate safety and efficacy of fix dOse combination of Metformin, glimePiride, and voglibose in Type 2 diabetes mellitus patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/01/017128
Enrollment
1000
Registered
2019-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Aprica Healthcare Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients willing to provide written informed consent at the time of enrolment 2.Male or Female patients above 18 years 3.Patients suffering from type 2 diabetes mellitus 4.Patients treated with fixed dose combination metformin, glimepiride and voglibose

Exclusion criteria

Exclusion criteria: 1.Patients receiving any other antidiabetic agent other than mentioned in inclusion criteria 2.Patients suffering from any other type of Diabetes except Type 2 diabetes mellitus

Design outcomes

Primary

MeasureTime frame
Evaluation of 1.Reduction in Fasting Blood Glucose (FBG) 2.Reduction in Post Prandial Blood Glucose (PPBG) 3.Reduction in HbA1C 4.Complications of Type 2 Diabetes Timepoint: 3 months—

Secondary

MeasureTime frame
Evaluation of following parameters 1.Demographic data of study participants 2.Comorbid conditions 3.Preferred Dose of Treatment 4.Dosage frequency 5.Administration time 6.Concomitant medications 7.Adverse events Timepoint: 3 months—

Countries

India

Contacts

Public ContactDr Amit Gajjar

Aprica Healthcare Pvt Ltd

dramit@aprican.com7573953504

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026